AEterna Zentaris Inc. (AEZS)
Stock Price:
$0.459 USD
-0.002 (-0.41%)
Updated Aug 6, 2020 3:29 PM EDT - Market open
Key Info
| Market Cap |
10.81M |
| Revenue (ttm) |
1.59M |
| Net Income (ttm) |
-6.04M |
| Shares Out |
41.13M |
| EPS (ttm) |
-0.02 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Aug 6, 2020 |
| Last Price |
$0.459 |
| Previous Close |
$0.461 |
| Change ($) |
-0.002 |
| Change (%) |
-0.41% |
| Day's Open |
0.465 |
| Day's Range |
0.443 - 0.470 |
| Day's Volume |
3,938,172 |
| 52-Week Range |
0.370 - 2.570 |
More Stats
| Market Cap |
10.81M |
| Enterprise Value |
3.51M |
| Earnings Date (est) |
n/a |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
41.13M |
| Float |
21.24M |
| EPS (basic) |
-0.35 |
| EPS (diluted) |
-0.02 |
| FCF / Share |
-0.61 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
164,450 |
| Short Ratio |
0.13 |
| Short % of Float |
1.67% |
| Beta |
2.59 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
6.82 |
| PB Ratio |
11.45 |
| Revenue |
1.59M |
| Operating Income |
-10.24M |
| Net Income |
-6.04M |
| Free Cash Flow |
-10.73M |
| Net Cash |
7.30M |
| Net Cash / Share |
0.31 |
| Gross Margin |
7.70% |
| Operating Margin |
-646.18% |
| Profit Margin |
-1,135.70% |
| FCF Margin |
-676.66% |
| ROA |
-25.51% |
| ROE |
-389.57% |
| ROIC |
256.70% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (0)
| Buy |
0 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Low
4.50
Current: $0.459
High
4.50
Target: 4.50
*Average 12-month price target from 1 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|
| Revenue | 0.53 | 26.88 | 0.92 | 0.91 | 0.55 | 0.01 | 6.18 | 2.05 | 4.71 | 27.70 |
| Revenue Growth | -98.02% | 2812.35% | 1.32% | 67.16% | 4854.55% | -99.82% | 200.78% | -56.37% | -83.02% | - |
| Gross Profit | 0.12 | 24.78 | 0.92 | 0.91 | 0.55 | 0.01 | 6.12 | 1.46 | 4.49 | 9.00 |
| Operating Income | -10.24 | 9.84 | -23.07 | -29.48 | -34.88 | -37.40 | -27.48 | -29.74 | -31.71 | -24.81 |
| Net Income | -6.04 | 4.19 | -16.80 | -24.96 | -50.14 | -16.56 | 6.82 | -20.41 | -27.07 | -28.45 |
| Shares Outstanding | 17.49 | 16.44 | 14.96 | 10.35 | 2.76 | 0.59 | 0.29 | 0.20 | 0.16 | 0.13 |
| Earnings Per Share | -0.35 | 0.24 | -1.12 | -2.41 | -18.14 | -28.06 | 23.12 | -103.00 | -172.00 | -226.00 |
| Operating Cash Flow | -10.73 | 6.83 | -22.91 | -29.01 | -33.84 | -31.08 | -19.98 | -30.82 | -26.24 | -31.71 |
| Capital Expenditures | - | 0.02 | 0.16 | -0.06 | 0.48 | -0.06 | -0.09 | -0.27 | -0.71 | -0.05 |
| Free Cash Flow | -10.73 | 6.84 | -22.76 | -29.07 | -33.37 | -31.14 | -20.07 | -31.09 | -26.95 | -31.76 |
| Cash & Equivalents | 8.20 | 14.93 | 8.16 | 22.50 | 41.71 | 35.69 | 44.07 | 40.35 | 47.69 | 34.76 |
| Total Debt | 0.90 | - | - | - | - | - | - | - | 0.06 | 0.06 |
| Net Cash / Debt | 7.30 | 14.93 | 8.16 | 22.50 | 41.71 | 35.69 | 44.07 | 40.35 | 47.63 | 34.70 |
| Assets | 19.98 | 25.01 | 22.20 | 31.66 | 51.50 | 47.44 | 59.20 | 67.67 | 75.37 | 61.45 |
| Liabilities | 22.44 | 23.10 | 24.98 | 25.45 | 29.88 | 32.95 | 42.13 | 74.36 | 79.92 | 79.02 |
| Book Value | -2.46 | 1.91 | -2.78 | 6.21 | 21.62 | 14.48 | 17.06 | -6.70 | -4.55 | -17.58 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
AEterna Zentaris Inc. |
| Country |
United States |
| CEO |
Klaus Paulini |
Stock Information
| Ticker Symbol |
AEZS |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: AEZS |
| IPO Date |
July 18, 1996 |
Description
Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing pharmaceutical therapies for treating oncology and endocrinology. Its commercial product is the Macrilen, a ghrelin receptor agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a, a ghrelin receptor, which is used for endocrinology and oncology indications. The company has a license and assignment agreement with Strongbridge Ireland Limited for the development, manufacturing, registration, and commercialization of Macrilen in the United States and Canada. Aeterna Zentaris Inc. was incorporated in 1990 and is headquartered in Summerville, South Carolina.